Key statistics
As of last trade Summit Therapeutics Inc (SMMT:NMQ) traded at 15.06, 8.89% above its 52-week low of 13.83, set on Feb 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 15.31 |
|---|---|
| High | 15.39 |
| Low | 14.85 |
| Bid | 15.05 |
| Offer | 15.07 |
| Previous close | 15.25 |
| Average volume | 3.02m |
|---|---|
| Shares outstanding | 744.44m |
| Free float | 103.82m |
| P/E (TTM) | -- |
| Market cap | 11.35bn USD |
| EPS (TTM) | -1.24 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 15:44 GMT.
More ▼
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
- Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
